Vanda Pharmaceuticals shares fall on failed Phase 3 trial for anxiety treatment
VNDA Vanda Pharmaceuticals Inc
$4.22 -1.86%
View chart & analysis → - 1Vanda Pharmaceuticals shares fell 6.2% in Wednesday after-hours trading.
- 2Vanda Pharmaceuticals announced that its anxiety treatment VQW-765 failed to meet the primary endpoint in a Phase 3 clinical trial.
- 3Vanda Pharmaceuticals has decided to pause the VQW-765 program pending further data analysis.
So what's the key point?
Vanda Pharmaceuticals' anxiety treatment did not achieve the desired results in its final stage of testing. The stock price fell 6.2% following this news.
Source Investing.com +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.